A new way of taking Tysabri (natalizumab) has been approved for the UK and Ireland.
The MHRA (Medicines and Healthcare products Regulatory Agency) and European Commission have granted marketing authorisation for an under-the-skin (subcutaneous) injection of Tysabri.
At the moment, it takes several hours to have a Tysabri infusion in a hospital clinic and some people have to travel a long distance to get to their infusion clinic.
Subcutaneous injections will take less time than the infusion and could be given in a clinic closer to home, such as at a local hospital or health centre. Monthly subcutaneous Tysabri will be given by a health professional.
Clinical trials have shown that monthly subcutaneous injections of Tysabri are as effective as monthly infusions at reducing relapses and lesions seen on MRI scans. About 7% of people (less than 1 in 10) experienced mild or moderate injection site reactions when having a subcutaneous injection of Tysabri.
More about Tysabri
Tysabri is a disease modifying drug for very active relapsing remitting MS (two or more relapses in one year, with signs of increasing or new lesions between two consecutive MRI scans). It reduces the number of relapses by about two thirds (70%), compared to taking placebo.
Common side effects include dizziness, nausea, urticaria (a skin rash) and shivering. Treatment with Tysabri may increase the risk of progressive multifocal leukoencephalopathy (PML), an uncommon brain infection.
Ozanimod (Zeposia) - NICE says no in final decision
13 May 2021 - 00:00
The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.
Machine learning identifies new subtypes of MS from MRI scans
13 May 2021 - 00:00
Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 Apr 2021 - 00:00
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.